Your browser doesn't support javascript.
loading
A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma.
Pace, Andrea; Mandoj, Chiara; Antenucci, Anna; Villani, Veronica; Sperduti, Isabella; Casini, Beatrice; Carosi, Mariantonia; Fabi, Alessandra; Vidiri, Antonello; Koudriavtseva, Tatiana; Conti, Laura.
Afiliação
  • Pace A; Neuroncology, Department of Clinical Experimental Oncology, Regina Elena National Cancer Institute, IFO, Via Elio Chianesi 53, 00144, Rome, Italy.
  • Mandoj C; Clinical Pathology, Department of Clinical Experimental Oncology, Regina Elena National Cancer Institute, IFO, Via Elio Chianesi 53, 00144, Rome, Italy.
  • Antenucci A; Clinical Pathology, Department of Clinical Experimental Oncology, Regina Elena National Cancer Institute, IFO, Via Elio Chianesi 53, 00144, Rome, Italy.
  • Villani V; Neuroncology, Department of Clinical Experimental Oncology, Regina Elena National Cancer Institute, IFO, Via Elio Chianesi 53, 00144, Rome, Italy.
  • Sperduti I; Biostatistics, Scientific Direction, Regina Elena National Cancer Institute, IFO, Via Elio Chianesi 53, 00144, Rome, Italy.
  • Casini B; Division of Pathology, "Regina Elena" National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
  • Carosi M; Division of Pathology, "Regina Elena" National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
  • Fabi A; Division of Medical Oncology, "Regina Elena" National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
  • Vidiri A; Service of Neuroradiology, "Regina Elena" National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
  • Koudriavtseva T; Neuroncology, Department of Clinical Experimental Oncology, Regina Elena National Cancer Institute, IFO, Via Elio Chianesi 53, 00144, Rome, Italy. tatiana.koudriavtseva@ifo.gov.it.
  • Conti L; Clinical Pathology, Department of Clinical Experimental Oncology, Regina Elena National Cancer Institute, IFO, Via Elio Chianesi 53, 00144, Rome, Italy.
J Neurooncol ; 138(3): 527-535, 2018 Jul.
Article em En | MEDLINE | ID: mdl-29594657
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Fator de von Willebrand / Bevacizumab / Antineoplásicos Imunológicos / Glioma / Recidiva Local de Neoplasia Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Neurooncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Fator de von Willebrand / Bevacizumab / Antineoplásicos Imunológicos / Glioma / Recidiva Local de Neoplasia Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Neurooncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália